318P - Antiproliferative effect of Moringaoleifera root extract on ovarian carcinoma: An in vitro study

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Ovarian Cancer
Cancer Biology
Presenter Arijit Ghosh
Citation Annals of Oncology (2016) 27 (suppl_9): ix94-ix103. 10.1093/annonc/mdw585
Authors A. Ghosh1, R. Bhattacharya1, C. Pradhan2, K. Chaudhuri1, A. Mukhopadhyay1, C.K. Bose1
  • 1Molecular Biology, Netaji Subhas Chandra Bose Cancer Research Institute, 700016 - Kolkata/IN
  • 2Human Genetics, Indian Institute of Chemical Biology, 700032 - Kolkata/IN



Ovarian cancer is the deadliest of gynecologic cancers worldwide, ranking as the third most common cancer among women, In India. Hence there is an unmet need to find out its etiology as well as cure. Previous reports have established the role of extracts of Moringa oleifera, a native tree from India, in attenuating breast or pancreatic cancer but not on ovarian cancer. Our aim of the present study was to understand the role Moringa oliefera on ovarian cancer, as its putative FSHR antagonistic role was suggested before.


To determine viability of ovarian cancer cells upon treatment with Moringa extract, the MTT assay was used, following standard protocol (1), with little modification. Briefly, OAW-42 (1 × 106 cells/ml) were cultured in a T-75 flask and transferred to a 96-well plate (1x104cells/well) and kept for one day at 37oC, then they were exposed to varying concentrations of Moringa root extract alone or in combination with sublethal toxicity dose of Paclitaxal or cisplatin, for 24 h. For both treated and control cells, Western blot analysis was performed using standard protocol to check its effect on apoptosis. To see the effect of Moringa root extract on cancer cell proliferation Clonogenic assay was carried out according to standard protocol (2).


The dose dependent analysison viabilityof OAW-42 cells by MTT assay showed 50% lethal toxicity (IC-50) of MRE (moringa root extract) to be 250μg/ml and even less (150µg/ml) in combinational treatment with cisplatin and Paclitaxal at a sublethal dose of their toxicity (250 mM and 30ng/ml respectively), without any apparent cytotoxicity on normal cells at the same dose. Our data showed MRE at its IC-50 value (250µg/ml) had effect in case of cleaved caspase-9. However it did not show much effect on cleaved caspase-8. In clonogenic assay approximately 40% reduction of colony formation was observed in treated plate than the control plate, indicating the potential of MRE in attenuating the survival of ovarian cancer cells.


We can conclude that MRE is a promising candidate for treatment of ovarian cancer, alone or in combination with traditional chemotherapeutic drugs like cisplatin and Paclitaxol at a sublethal dose of their toxicity.

Clinical trial indentification


Legal entity responsible for the study



Netaji Subhas Chandra Bose Cancer Research Institute


All authors have declared no conflicts of interest.